The 21-gene recurrence score can predict the benefits of adjuvant chemotherapy for certain breast cancer patients, but its effectiveness varies by race. A study published found that the score is a predictive biomarker for most early-stage estrogen receptor (ER)-positive, HER2-negative breast cancer cases. Asian or Pacific Islander patients did not benefit from the score, and it underestimated the benefits of adjuvant chemotherapy for non-Hispanic Black patients under 50. The research analyzed data on 73,363 patients with stage I-II, ER-positive, HER2-negative, axillary node-negative breast cancer, and found that adjuvant chemotherapy was associated with a significant reduction in the risk of breast cancer death for certain patient groups. Further studies are needed to confirm these findings.
Source link
Effectiveness of Breast Cancer Recurrence Score Varies by Race
